= ltem2of20 5 v Mark <q Se r j @ él fcc]

; Le c
Question Id: 18613 Praras Next FullScreen Tutorial__—_Lab Values Notes

A 65-year-old woman is enrolled in a clinical trial to test a new medication for rheumatoid
arthritis. The patient's condition has been poorly controlled despite prolonged treatment with
multiple disease-modifying antirheumatic drugs. The new medication is a CTLA4-lg fusion
protein that prevents CD28 from binding to CD80/86 on antigen-presenting cells. A month
after treatment begins, the patient reports a significant reduction in joint pain and stiffness.
Laboratory results reveal reduced levels of C-reactive protein and IL-2. Which of the following
is the most likely underlying cause of this patient's treatment response?

A. Complement inhibition (13%)

B. Immune complex clearance (13%)

C. Negative selection (13%)
YD. Peripheral tolerance (52%)

E. Sensitization (6%)

Omitted
Correct answer lil

D

52% 05 secs c4 2022
Answered correctly Time Spent [3] Version

Block Time Elapse

Tutor

‘J

Calculator _ Reverse Color

GAA)

Text Zoom

Activate Windows

Feedback

id

63

Settings

End Block
